A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With an Open-Label Extension Evaluating Extended Release OROS Paliperidone in the Prevention of Recurrence in Subjects With Schizophrenia - Open Label Phase.
Phase of Trial: Phase III
Latest Information Update: 20 May 2009
At a glance
- Drugs Paliperidone (Primary)
- Indications Schizophrenia
- Focus Adverse reactions
- Sponsors Janssen Research & Development
- 31 Aug 2018 Biomarkers information updated
- 14 Apr 2008 New trial record.